Following a recent funding round raising $8.8 million, Auckland biotech company Pictor today announced it has received confirmation of CE registration for its PictArray™ SARS-CoV-2 IgG enzyme-linked
immunosorbent assay (ELISA) antibody test as per In Vitro Diagnostic Directive (IVDD) regulations.
The CE Mark will allow the company to market its COVID-19 antibody test in Europe and gain regulatory approval in
Southeast Asia.
“Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within
Europe, which is an important market for us,” says Pictor CEO Howard Moore. “Our recent successful funding round means
we are well equipped to support market development and launches within the European Economic Area while continuing
existing work across Australasia, the United States, India and Southeast Asia.”Pictor’s PictArray antibody test provides personalised results
Pictor’s PictArrayTM SARS-CoV-2 assay, the first test of its kind, will enable personalised COVID-19 assessments by
detecting if a patient has antibodies from a previous infection of SARS-CoV-2 (from spike protein (SP) and nucleocapsid
protein (NP) antibodies) or from vaccination alone (SP antibodies only). It will also indicate whether at-risk patients
have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).
The PictArray™ SARS-CoV-2 antibody test will be available in New Zealand from July 2022 via medical testing laboratories
IGENZ (www.igenz.co.nz) and Rako Science (www.rakoscience.com).
“As we learn more about COVID-19, the separate detection of SP and NP will enable a more precise assessment of a
patient’s immunity against SARS-CoV-2 and help guide any associated clinical interventions while also informing wider
public health measures when mass serosurveys are conducted,” explains Pictor’s Chief Medical Officer Tadd Lazarus, MD.
The COVID-19 pandemic remains a healthcare concern as new strains of the virus have emerged. According to recent data,
COVID-19 cases are up significantly in many U.S.states and Europe. According to a March 31 statement by the World Health Organization in its weekly epidemiological update, "COVID-19
remains a Public Health Emergency of international concern, and it is too early to reduce the quality of surveillance.”